Its a drug supplying company. Their primary focus is to provide medicine for genetic diseases safely and quickly to the patients. They have created the bridge between genetic science advancement and patients. They approach the entrepreneurial engine, which, they think, is necessary to make life-changing medicines. BridgeBio finds prodigious science where the mechanism of a syndrome is well-understood and cultivates medicines that aim those diseases at their source. They also bring advanced biotech companies and genetic research departments together to generate procedures needed to develop multiple individual therapies instantaneously. Their regionalized subsidiary model lets them allocate shared central resources while staying hyper-focused on developing therapies for each disease. In just three years, BridgeBio has more than 15 drug programs for 20 genetic diseases – which they consider decreases the traditional biopharma process by years. The model they follow creates efficiency, rigor, and scale, empowering their teams to make objective, data-driven conclusions rapidly across numerous programs.
Similar companies
